+ Translate
+ Most Popular
Advantages and disadvantages of bordeaux mixture and of lime-sulphur used on apples in the growing season
Observations on the Umaria marine bed
10 years of hearing conservation in the Royal Air Force
Chocolate crumb - dairy ingredient for milk chocolate
Effect of daily gelatin ingestion on human scalp hair
Comparison of rice bran and maize bran as feeds for growing and fattening pigs
The composition of pampas-grass (Cortaderia argentea.)
The Accraian Series:
The mechanism of the Liebermann-Burchard reaction of sterols and triterpenes and their esters
Cerebrovascular Doppler ultrasound studies (cv-Doppler)
Toria: PT-303 - first national variety
Hair growth promoting activity of tridax procumbens
Productivity of Pekin x Khaki Campbell ducks
A stable cytosolic expression of VH antibody fragment directed against PVY NIa protein in transgenic potato plant confers partial protection against the virus
Solar treatment of wheat loose smut
Swimmers itch in the Lake of Garda
Bactofugation and the Bactotherm process
The effects of prefrontal lobotomy on aggressive behavior in dogs
Visual rating scales for screening whorl-stage corn for resistance to fall armyworm
Breakdown of seamounts at the trench axis, viewed from gravity anomaly
Kooken; pennsylvania's toughest cave
Recovery of new dinosaur and other fossils from the Early Cretaceous Arundel Clay facies (Potomac Group) of central Maryland, U.S.A
Zubor horny (Bison bonasus) v prirodnych podmienkach Slovensku
The extended Widal test in the diagnosis of fevers due to Salmonella infection
Hair of the american mastodon indicates an adaptation to a semi aquatic habitat

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

European Journal of Nuclear Medicine 26(8): 877-886

ISSN/ISBN: 0340-6997

PMID: 10436201

DOI: 10.1007/s002590050462

Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe(1)-Tyr(3)-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with (90)Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 microg), labelled with 150-185 MBq of (111)In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of >37 GBq/ micromol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for (111)In-DOTATOC in blood was 0.9+/-0.4 h. The injected activity excreted in the urine in the first 24 h was 73%+/-11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2+/-1.8 h in spleen, 1.7+/-1.2 h in kidneys, 2.4+/-1.9 h in liver, 1.5+/-0.3 h in urinary bladder and 9. 4+/-5.5 h in the remainder of the body; the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for (90)Y-DOTATOC would be 7.6+/-6.3 (spleen), 3.3+/-2.2 (kidneys), 0.7+/-0.6 (liver), 2.2+/-0.3 (bladder), 0.03+/-0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of (90)Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation doses to the spleen and kidneys. Tumour doses were high enough in most cases to make it likely that the desired therapeutic response desired would be obtained.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 045376725

Download citation: RISBibTeXText

Related references

Biokinetics and dosimetry in patients administered with111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with90Y-DOTATOC. European Journal of Nuclear Medicine and Molecular Imaging 26(8): 877-886, 1999

(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics 6(4): 501-510, 2016

Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide. European Journal of Nuclear Medicine and Molecular Imaging 39(12): 1868-1875, 2012

2269 [177Lu-Dota]-D-Phe1-Tyr3-octreotide (177Lu-Dotatoc) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: A retrospective phase Ii study of efficacy and safety. European Journal of Cancer 51: S422-S423, 2015

Bone marrow dose results in peptide receptor radionuclide therapy with 90Y-DOTA-Tyr3-Octreotide, 111In-DTPA-Octreotide and 177Lu-DOTA-Octreotate Importance of dosimetry model. Journal of Nuclear Medicine 43(5 Suppl.): 90P, 2002

Organ and tumor dosimetry of 177Lu-DOTA-Tyr3-octreotate and 90Y-DOTA-Tyr3-octreotide A preliminary study in 2 patients. Journal of Nuclear Medicine 43(5 Suppl.): 316P, 2002

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 33(5): 532-540, 2006

177 Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer. Contrast Media and Molecular Imaging 2018: 5247153, 2018

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 31(7): 1038-1046, 2004

Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits. Applied Radiation and Isotopes: Including Data Instrumentation and Methods for use in Agriculture Industry and Medicine 64(7): 792-797, 2006

68Ga-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC)-PET/CT in a Suspected Case of Recurrent Meningioma. Indian Journal of Nuclear Medicine: Ijnm: the Official Journal of the Society of Nuclear Medicine India 32(2): 164, 2017

(68) Ga- DOTA(0) -Tyr(3) octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours. Clinical Endocrinology 81(1): 152-153, 2014

Biodistribution and dosimetry of indium-111 labeled DOTA-Tyr3-octreotide in patients with neuroendocrine tumors. Journal of Nuclear Medicine 39(5 Suppl. ): 221P, 1998

Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue. Clinical Oncology ) 12(2): 121-123, 2000

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 31(10): 1386-1392, 2004